Not available
Quote | Audentes Therapeutics Inc. (NASDAQ:BOLD)
Last: | $4.18 |
---|---|
Change Percent: | 1.17% |
Open: | $4.24 |
Close: | $4.18 |
High: | $4.49 |
Low: | $4.09 |
Volume: | 71,022 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
News | Audentes Therapeutics Inc. (NASDAQ:BOLD)
Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer,...
2024-05-13 09:47:09 ET More on Boundless Bio, Inc. Boundless Bio Starts $100 Million U.S. IPO Plan Bayer-backed Boundless Bio sees stock fall 8% after $100M IPO Boundless Bio prices $100M IPO at $16 per share Historical earnings data for Boundless Bio, Inc. ...
Message Board Posts | Audentes Therapeutics Inc. (NASDAQ:BOLD)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Audentes Therapeutics Inc. Company Name:
BOLD Stock Symbol:
NASDAQ Market:
Audentes Therapeutics Inc. Website:
Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer,...
BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2 STARMAP clinical trial of BBI-825 in patients with tumors with resistance gene amplifications ...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Boundless Bio Chief Financial Officer, Jami Rubin, will...